Every trial is a point of light. The closer to the centre, the closer it is to patients. The higher it floats, the more directly it aims to change the course of the disease.
The centre is the disease. Around it, each sector is one angle of attack: genes and RNA, inflammation, protein clean-up, cells, devices, care and so on. Click a sector name to enter it.
Distance from the centre is how close an effort is to patients. The innermost ring holds treatments a regulator has approved. Then late-stage trials (Phase 3 to 4), Phase 2, Phase 1, and on the outside the studies with no phase: observational research, devices and care.
Height and colour show what the trial measures first. Top: slowing or stopping the disease (survival, rate of decline). Next: easing symptoms and keeping function, which buys time. Then early safety testing. On the ground: understanding the disease. Grey points did not state a primary measure we could read.
Brightness is status: bright points are recruiting or about to; dim points are finished; the faintest were stopped early. Size is the number of people enrolled or planned.
Lines on the ground are treatments, drawn from the edge to the furthest stage each has reached. Columns at the edge are money: research grants for that angle of attack in the last complete year, from the funders we can read.
What this is not. Sectors and aims are assigned automatically from keywords in each registry record, to help you navigate. They are not a scientific judgement, and a trial's aim is not its result. Money covers public and charitable grants from funders with an open data service. It leaves out industry spending and several large ALS charities, so it is a floor, not the world total. Always open the registry record before relying on anything here.
This view needs WebGL, which is not available in this browser.